T Cell News and Research

Latest T Cell News and Research

Air pollution can damage heart and lead to increased risk of heart disease: Study

A post-mortem study of the hearts of 21 young people in Mexico City has found that the heart begins to show the adverse effects of air pollution at a young age and that tiny bits of inactivated bacteria that hitch a ride on pollutants may make the problem worse.

29 Apr 2010

CD8+T cells may aid in developing AIDS vaccine: New Journal of Physics

Limited success in modelling the behaviour of the complex, unusual and unpredictable HIV virus has slowed efforts to develop an effective vaccine to prevent AIDS.

29 Apr 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

The SPEDOC project will create the precursor to future devices for individualized diagnosis and monitoring of cancer therapy, which will allow the illness to be treated in earlier stages and at lower doses, reducing or preventing current secondary effects.

29 Apr 2010

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

MU researcher develops test to pinpoint neurological origins of dysphagia

Muscle degeneration and confinement to a wheelchair are the hallmarks of Lou Gehrig's disease, Parkinson's, muscular dystrophy and other neurodegenerative diseases. One of the silent, and most serious, symptoms of these diseases is losing the ability to swallow.

29 Apr 2010

ATIR shows better clinical results in patients receiving mismatched bone marrow transplantation

Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

New study reinforces urgent need for life-saving vaccines in Africa

A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death.

29 Apr 2010

NIH approves federal funding for 13 more stem cell lines

The Washington Post: Thirteen more lines of human embryonic stem cells are officially eligible for federal funding, since being approved by the National Institutes of Health. The Obama administration announced shortly after the President took office that restrictions would be lifted on the use of federal funds for embryonic stem cell research.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a clinical cell line development services company, jointly announced today their collaborative agreement to create a business model enabling customers to access their one stop shop services.

28 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Scientists discover human DNA that act as a traitor to body's defences

Cancer Research UK-funded scientists have discovered that stretches of human DNA act as a traitor to the body's defences by helping viruses infect people and trigger cancer-causing diseases, according to a study published in Nature Cell Biology today.

28 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

T Cell News and Research

Latest T Cell News and Research

Air pollution can damage heart and lead to increased risk of heart disease: Study

CD8+T cells may aid in developing AIDS vaccine: New Journal of Physics

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

Physicists and oncologists to develop novel ultra sensitive platform for early cancer detection

Geron reports net loss of $16.6M for first-quarter 2010

MU researcher develops test to pinpoint neurological origins of dysphagia

ATIR shows better clinical results in patients receiving mismatched bone marrow transplantation

Study calls for optimized medical treatment for older patients with advanced lung cancer

Combination of antibiotics can cure Chlamydia-induced ReA: Study

A new approach for treating neurological and degenerative disorders

New study reinforces urgent need for life-saving vaccines in Africa

NIH approves federal funding for 13 more stem cell lines

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Tumor cell factories may be difficult to defeat: Researchers

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Celera reports net loss of $12.5M for first-quarter 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Scientists discover human DNA that act as a traitor to body's defences

Stalk structure of Mx protein restrains components of influenza virus in infected cells

Research reveals therapeutic benefit of ACTH in treatment of osteonecrosis

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in